{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T23:18:26Z","timestamp":1789859906666,"version":"4.0.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Emergency Medicine"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.ajem.2017.03.010","type":"journal-article","created":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T14:21:54Z","timestamp":1488896514000},"page":"1172-1176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Emerging trends in antibiotic resistance: Implications for emergency medicine"],"prefix":"10.1016","volume":"35","author":[{"given":"Ali","family":"Pourmand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryann","family":"Mazer-Amirshahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Jasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajem.2017.03.010_bb0005","author":"Antibiotic\/Antimicrobial Resistance. Centers for Disease Control and Prevention"},{"key":"10.1016\/j.ajem.2017.03.010_bb0010","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1093\/cid\/civ201","article-title":"Antibacterial drug shortages from 2001 to 2013: implications for clinical practice","volume":"60","author":"Quadri","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ajem.2017.03.010_bb0015","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"issue":"32","key":"10.1016\/j.ajem.2017.03.010_bb0020","first-page":"707","article-title":"Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus \u2014 Minnesota and North Dakota, 1997\u20131999","volume":"48","author":"Centers for Disease Control and Prevention (CDC)","year":"1999","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ajem.2017.03.010_bb0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.7326\/0003-4819-96-1-11","article-title":"Methicillin-resistant Staphylococcus aureus. Epidemiologic observations during a community-acquired outbreak","volume":"96","author":"Saravolatz","year":"1982","journal-title":"Ann Intern Med"},{"issue":"Suppl. C","key":"10.1016\/j.ajem.2017.03.010_bb0030","doi-asserted-by":"crossref","first-page":"4C","DOI":"10.1155\/2006\/971352","article-title":"Guidelines for the prevention and management of community-associated methicillin-resistant Staphylococcus aureus: a perspective for Canadian health care practitioners","volume":"17","author":"Barton","year":"2006","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.ajem.2017.03.010_bb0035","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"10.1016\/j.ajem.2017.03.010_bb0040","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1128\/JCM.00254-06","article-title":"Comparisons of community-associated methicillin-resistant Staphylococcus aureus (MRSA) and hospital-associated MRSA infections in Sacramento California","volume":"44","author":"Huang","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ajem.2017.03.010_bb0045","doi-asserted-by":"crossref","DOI":"10.18203\/2320-6012.ijrms20162275","article-title":"Clinico-microbiological study of community acquired and health care associated methicillin-resistant Staphylococcus aureus from skin and soft tissue infections","author":"John","year":"2016","journal-title":"Int J Res Med Sci"},{"key":"10.1016\/j.ajem.2017.03.010_bb0050","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1056\/NEJMoa055356","article-title":"Methicillin-resistant S. aureus infections among patients in the emergency department","volume":"355","author":"Moran","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2017.03.010_bb0055","series-title":"Environmental risk factors for community-acquired MRSA","author":"Friedman","year":"2015"},{"key":"10.1016\/j.ajem.2017.03.010_bb0060","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1128\/AAC.00377-07","article-title":"Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection","volume":"51","author":"Rajendran","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ajem.2017.03.010_bb0065","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ajem.2017.03.010_bb0070","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1093\/cid\/cit613","article-title":"Methicillin-resistant Staphylococcus aureus: an evolving pathogen","volume":"58","author":"Stryjewski","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ajem.2017.03.010_bb0075","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/nrmicro2761","article-title":"The rise of the Enterococcus: beyond vancomycin resistance","volume":"10","author":"Arias","year":"2012","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ajem.2017.03.010_bb0080","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1128\/AAC.02684-13","article-title":"Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012)","volume":"58","author":"Sader","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ajem.2017.03.010_bb0085","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1086\/666331","article-title":"Association of vancomycin-resistant enterococcus bacteremia and ceftriaxone usage","volume":"33","author":"McKinnell","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ajem.2017.03.010_bb0090","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00024382-200014030-00003","article-title":"Reduction of vancomycin-resistant enterococcal infections by limitation of broad-spectrum cephalosporin use in a trauma and burn intensive care unit","volume":"14","author":"May","year":"2000","journal-title":"Shock"},{"key":"10.1016\/j.ajem.2017.03.010_bb0095","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/cid\/civ444","article-title":"Comparison of the effectiveness and safety of linezolid and daptomycin in vancomycin-resistant enterococcal bloodstream infection: a National Cohort Study of Veterans Affairs Patients","volume":"61","author":"Britt","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ajem.2017.03.010_bb0100","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01289-13","article-title":"Systematic review and meta-analysis of linezolid vs daptomycin for treatment of vancomycin resistant enterococcal bacteremia","volume":"58","author":"Balli","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ajem.2017.03.010_bb0105","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0924-8579(98)00021-1","article-title":"A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women","volume":"10","author":"Minassian","year":"1998","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ajem.2017.03.010_bb0110","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"10.1016\/j.ajem.2017.03.010_bb0115","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1128\/AAC.01760-09","article-title":"Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-B-lactamase producing E. coli","volume":"54","author":"Auer","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ajem.2017.03.010_bb0120","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ajem.2017.03.010_bb0125","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.ajem.2017.03.010_bb0130","first-page":"638","article-title":"Recurrent urinary tract infection in women: diagnosis and management","volume":"82","author":"Kodner","year":"2010","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.ajem.2017.03.010_bb0135","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/archinternmed.2012.777","article-title":"Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women","volume":"172","author":"Beerepoot","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ajem.2017.03.010_bb0140","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jemermed.2014.06.037","article-title":"Septic shock and adequacy of early empiric antibiotics in the emergency department","volume":"47","author":"Flaherty","year":"2014","journal-title":"J Emerg Med"},{"key":"10.1016\/j.ajem.2017.03.010_bb0145","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jemermed.2010.10.024","article-title":"Effective antibiotic treatment prescribed by emergency physicians in patients admitted to the intensive care unit with severe sepsis or septic shock: where is the gap?","volume":"41","author":"Capp","year":"2011","journal-title":"J Emerg Med"},{"key":"10.1016\/j.ajem.2017.03.010_bb0150","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ajem.2017.03.010_bb0155","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12879-015-1054-1","article-title":"Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options","volume":"15","author":"Golan","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.ajem.2017.03.010_bb0160","first-page":"149","article-title":"Isepamicin versus amikacin in the treatment of urinary tract infection","volume":"7","author":"Sturm","year":"1995","journal-title":"J Chemother"},{"key":"10.1016\/j.ajem.2017.03.010_bb0165","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1473-3099(15)00424-7","article-title":"Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study","volume":"16","author":"Liu","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ajem.2017.03.010_bb0170","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1128\/AAC.01103-16","article-title":"Escherichia coli harboring mcr-1 and blaCTX-M on a novel IncF plasmid: first report of mcr-1 in the United States","volume":"60","author":"McGann","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ajem.2017.03.010_bb0175","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2110-5820-1-14","article-title":"Renal and neurological side effects of colistin in critically ill patients","volume":"1","author":"Spapen","year":"2011","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.ajem.2017.03.010_bb0180","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1001\/jama.2008.896","article-title":"Carbapenem-resistant Enterobacteriaceae: a potential threat","volume":"300","author":"Schwaber","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.ajem.2017.03.010_bb0185","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.diagmicrobio.2009.08.020","article-title":"Summary trends for the meropenem yearly susceptibility test information collection program: a 10-year experience in the United States (1999\u20132008)","volume":"65","author":"Rhomberg","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ajem.2017.03.010_bb0190","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1086\/592412","article-title":"Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies","volume":"29","author":"Patel","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ajem.2017.03.010_bb0195","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4065\/mcp.2010.0674","article-title":"Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa","volume":"86","author":"Kanj","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ajem.2017.03.010_bb0200","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/jac\/dkq191","article-title":"Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination","volume":"65","author":"Perez","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ajem.2017.03.010_bb0205","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1586\/erp.10.49","article-title":"Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes","volume":"10","author":"Hirsch","year":"2010","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.ajem.2017.03.010_bb0210","doi-asserted-by":"crossref","first-page":"S627","DOI":"10.1093\/clinids\/6.Supplement_3.S627","article-title":"Epidemiology of infections due to Pseudomonas aeruginosa","volume":"6","author":"Morrison","year":"1984","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.ajem.2017.03.010_bb0215","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1128\/AAC.49.4.1306-1311.2005","article-title":"Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment","volume":"49","author":"Micek","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ajem.2017.03.010_bb0220","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/clinids\/10.3.629","article-title":"Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes","volume":"10","author":"Bisbe","year":"1988","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.ajem.2017.03.010_bb0225","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ajem.2017.03.010_bb0230","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1128\/AAC.50.1.43-48.2006","article-title":"Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact","volume":"50","author":"Aloush","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ajem.2017.03.010_bb0235","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1001\/archinte.159.10.1127","article-title":"Health and economic outcomes of antibiotic resistant Pseudomonas aeruginosa","volume":"159","author":"Carmeli","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ajem.2017.03.010_bb0240","doi-asserted-by":"crossref","first-page":"526e19","DOI":"10.1016\/j.amjmed.2005.11.029","article-title":"Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact","volume":"119","author":"Gasink","year":"2006","journal-title":"J Med"},{"key":"10.1016\/j.ajem.2017.03.010_bb0245","first-page":"159","article-title":"Clinical outcomes and costs of care of antibiotic resistant Pseudomonas aeruginosa infections","volume":"32","author":"Dimatatac","year":"2003","journal-title":"Philipp J Microbiol Infect Dis"},{"key":"10.1016\/j.ajem.2017.03.010_bb0250","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1128\/AAC.00325-11","article-title":"Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone","volume":"55","author":"Ohnishi","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ajem.2017.03.010_bb0255","author":"Centers for Disease Control and Prevention.2010"},{"key":"10.1016\/j.ajem.2017.03.010_bb0260","author":"Centers for Disease Control and Prevention.2015"},{"key":"10.1016\/j.ajem.2017.03.010_bb0265","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3201\/eid1701.100397","article-title":"Ceftriaxone-resistant Neisseria gonorrhea, Japan","volume":"17","author":"Ohnishi","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ajem.2017.03.010_bb0270","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.ajem.2017.03.010_bb0275","author":"The White House"},{"issue":"24","key":"10.1016\/j.ajem.2017.03.010_bb0280","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.2146\/ajhp140832","article-title":"Comparison of antibiotic susceptibility of Escherichia coli in urinary isolates from an emergency department with other institutional susceptibility data","volume":"72","author":"Zatorski","year":"2015","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ajem.2017.03.010_bb0285","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.2146\/ajhp130079","article-title":"Comparison of bacteria isolated from emergency department patients versus hospitalized patients","volume":"70","author":"Draper","year":"2013","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ajem.2017.03.010_bb0290","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ajic.2012.02.021","article-title":"Clinical and economic outcomes from a hospital's antimicrobial stewardship program","volume":"41","author":"Malani","year":"2013","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.ajem.2017.03.010_bb0295","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.annemergmed.2012.09.002","article-title":"A call to action for antimicrobial stewardship in the emergency department: approaches and strategies","volume":"62","author":"May","year":"2013","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.ajem.2017.03.010_bb0300","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.ajem.2017.03.010_bb0305","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.ajem.2017.03.010_bb0310","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.ajem.2017.03.010_bb0315","author":"American College of Emergency Physicians"},{"key":"10.1016\/j.ajem.2017.03.010_bb0320","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ajem.2016.10.034","article-title":"A review of newly approved antibiotics and antibiotics reserved for resistant infections: implications for emergency medicine","volume":"35","author":"Mazer-Amirshahi","year":"2017","journal-title":"Am J Emerg Med"}],"container-title":["The American Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675717301766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675717301766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T15:36:53Z","timestamp":1760024213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735675717301766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":64,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0735675717301766"],"URL":"https:\/\/doi.org\/10.1016\/j.ajem.2017.03.010","relation":{},"ISSN":["0735-6757"],"issn-type":[{"value":"0735-6757","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging trends in antibiotic resistance: Implications for emergency medicine","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajem.2017.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}